TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Pharmaust Limited ( (AU:NUZ) ) is now available.
Neurizon Therapeutics Limited announced that the U.S. FDA has lifted the clinical hold on its investigational drug, NUZ-001, marking a significant regulatory milestone for the company and the ALS community. This clearance allows Neurizon to proceed with the Phase 2/3 development of NUZ-001 as part of the HEALEY ALS Platform Trial, expected to start in Q4 2025. The decision is supported by robust preclinical safety data and a comprehensive manufacturing framework, positioning Neurizon for accelerated regulatory pathways and future partnerships. The IND for NUZ-001 not only expedites its development but also streamlines future programs, enhancing the drug’s potential as a therapeutic platform with broad applicability.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.52 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is advancing its lead drug candidate, NUZ-001, for the treatment of ALS, the most common form of motor neurone disease. Neurizon aims to accelerate access to effective ALS treatments and explore broader neurodegenerative applications through international collaborations and rigorous clinical programs.
YTD Price Performance: -14.71%
Average Trading Volume: 508,020
Technical Sentiment Signal: Sell
Current Market Cap: A$77.51M
Learn more about NUZ stock on TipRanks’ Stock Analysis page.